Mental and Neurological
-
Cost-Effectiveness of Long-Acting Risperidone in Sweden
Hensen M, Heeg B, Löthgren M, van Hout B. Applied Health Economics and Health Policy. 2010; 8(5): 327-341.
-
Economic Outcomes of Eszopiclone Treatment in Insomnia and Comorbid Major Depressive Disorder
Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS. The Journal of Mental Health Policy and Economics 2010; 13(1):27-35.
-
Health economics of insomnia therapy: implications for policy.
Botteman MF. Sleep Med. 2009;10(S1):S22-5 (link to PDF)
-
Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.
Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Sleep 2009;32(6):817-24 (link to PDF)
-
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
Treur M, Heeg B, Möller H, Schmeding, van Hout B. BMC Health Serv Res. 2009;9(32):1-9.
(link to PDF)
-
Modelling approaches: the case of schizophrenia.
Heeg BM, Damen J, Buskens E, Caleo S de Charro F van Hout BA. Pharmacoeconomics 2008;26(8):633-48 (link to PDF)
-
The cost-effectiveness of atypicals in the UK.
Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, van Hout B. Value Health 2008;11(7):1007-21 (link to PDF)
-
A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
Damen J, Thuresson PO, Heeg B, Lothgren M. Appl Health Econ Health Policy 2008;6(4):189-97 (link to PDF)
-
Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.
Heeg BM, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Van Hout BA. Curr Med Res Opin. 2008;24(2):349-58. (link to PDF)
-
Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults : a decision analytical model.
Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. CNS Drugs. 2007; 21(4): 319-34.
-
Psychosocial impact of finding small aneurysms that are left untreated in patients previously operated on for ruptured aneurysms.
van der Schaaf IC, Wermer MJ, Velthuis BK, Buskens E, Bossuyt PM, Rinkel GJ. J Neurol Neurosurg Psychiatry. 2006;77(6):748-52.
-
Feasibility and cost efficiency of a diagnostic guideline for chronic polyneuropathy: a prospective implementation study.
Vrancken AF, Kalmijn S, Buskens E, Franssen H, Vermeulen M, Wokke JH, Notermans NC. J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):397-401. Erratum in: J Neurol Neurosurg Psychiatry. 2006;77(5):710.
-
Cost-Effectiveness Model Of Long-Acting Risperidone in Schizophrenia in the US.
Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Pharmacoeconomics 2005;23(3):299-314.
-
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS, Heeg B, Buskens E, van Hout BA. Pharmacoeconomics. 2005;23 Suppl 1:62-74.
-
Modelling the treated course of schizophrenia: development of a discrete event simulation model.
Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, van Hout BA. Pharmacoeconomics. 2005;23 Suppl 1:17-33.
|
,
View by subject
|
